Sermorelin
A synthetic first-29-amino-acid fragment of GHRH — the minimum retaining full receptor activity — and a former FDA-approved drug (Geref) for paediatric growth hormone deficiency until manufacturer withdrawal in 2008. Reportedly investigated off-label for adult GH optimisation, anti-aging, and body composition; it signals the pituitary to release endogenous GH. The strongest evidence addresses the former approved paediatric indication; controlled evidence for the adult applications most frequently discussed is limited.
Side effects & risks
Sermorelin carries a meaningful, characterised human safety profile by the standards of this compound class, because it was once an FDA-approved drug (Geref; diagnostic formulation approved 1990, therapeutic paediatric GHD formulation approved 1997) and accumulated controlled-trial data before its market withdrawal. That history does not eliminate risk; it provides a better-characterised baseline than most research peptides.
In the pivotal paediatric trials supporting FDA approval, the most commonly reported adverse events were injection-site reactions — redness, pain, and swelling — occurring in a minority of subjects. Flushing, headache, and nausea were also reported at low frequency. These trials enrolled children with growth hormone deficiency, a population and indication that is not comparable to adult off-label use.
A theoretical concern shared with all compounds that stimulate growth hormone release is the potential for IGF-1-mediated effects over extended administration periods. Elevated IGF-1 has been associated with increased cancer risk in epidemiological studies (Pollak MN, Schernhammer ES, Hankinson SE, 2004, Nature Reviews Cancer, vol. 4, no. 7; PMID 15229476); the causal relationship is complex and the clinical magnitude of any risk from exogenous GHRH stimulation in adults is not established in peer-reviewed literature.
The manufacturer voluntarily withdrew Geref from the US market in 2008 for commercial, not safety, reasons; the FDA formally withdrew the marketing approval in June 2009. Compounded sermorelin for adults is prepared and sold as a research chemical in the US; this use has not been evaluated in dedicated large-scale human trials. Safety data from paediatric growth hormone deficiency trials should not be extrapolated uncritically to adult use, different dose regimens, or self-reported community administration practices.
Drug interactions have not been systematically characterised for compounded adult use. Concomitant use with other growth hormone secretagogues or exogenous growth hormone may compound IGF-1 effects. Individuals with a personal or family history of cancer, particularly hormone-sensitive cancers, should seek clinical advice before considering any GH-stimulating compound.
Sermorelin is not approved for human therapeutic use in the United States in its current compounded form. Its prior FDA approval was for a specific paediatric indication via a branded product that is no longer marketed. Individuals obtaining compounded sermorelin as a research chemical assume risk in a context that is distinct from the original clinical trial programme.
Evidence summary
Latest studies
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.
This review discussed the growing use of peptides and peptide-like drugs to enhance muscle, fat loss and recovery in sport and bodybuilding. It is an expert commentary summarising the field, not a new experiment. The authors explained that these peptides, including growth-hormone-releasing peptides such as ipamorelin, growth-hormone-releasing hormone analogues such as CJC-1295 and sermorelin, and fragments such as Frag 176-191 and KPV, are promoted as more selective and supposedly safer than anabolic steroids. However, they stressed that the clinical evidence is limited, because most studies tested careful medical doses, not the very high or combined doses often used in bodybuilding. They pointed to emerging risks including strain on the heart, insulin resistance, abnormal blood fats, and mood and psychiatric instability, and warned that a largely unregulated supply means products are often mislabelled or contaminated. They also noted that how widely these peptides are used, especially among ordinary gym-goers and younger people, is simply unknown. The authors concluded that peptides remain experimental substances with poorly understood long-term risks, and that until long-term studies exist, their use in competitive and recreational settings should be regarded as high-risk and ethically problematic.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
This review article, published in Sports Medicine, set out to map what is known — and what is not known — about eleven peptides being used or marketed in sports medicine settings, both those approved by regulators and those sold outside formal regulatory oversight. The peptides examined include tesamorelin (FDA-approved for fat redistribution in HIV patients), sermorelin (a former FDA-approved drug, now discontinued), CJC-1295, ipamorelin, BPC-157, TB-500, GHK-Cu, AOD-9604, follistatin-344, MOTS-c, and thymosin beta-4. The authors reviewed existing published research on each compound's biological mechanisms, known safety information, and current regulatory status. The review found that many unapproved peptides show promising results for tissue repair and metabolism in animal studies, but that rigorous human safety data are largely absent. The authors noted that this creates meaningful risk for patients using these compounds outside medical supervision. A parallel gray market has grown up around these products, operating with little regulatory oversight. The review also highlighted two factors that shape how people perceive peptide benefits beyond any direct biological effect: the placebo effect and social media, which together may amplify expectations and reported outcomes in ways that are difficult to separate from pharmacological action. The authors propose a framework to help clinicians discuss peptide use with patients and to support evidence-based...
Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
This study is about detecting drugs, not about their effects. Certain lab-made peptides related to growth-hormone-releasing hormone (GHRH), including sermorelin, tesamorelin, and CJC-1295, are banned in sport by the World Anti-Doping Agency. They are hard to detect in urine because they break down quickly, are cleared from the body fast, and appear only at tiny concentrations. The researchers built and tested a sensitive laboratory technique, combining a miniaturised form of liquid chromatography with high-resolution mass spectrometry, to screen for and confirm these peptides and a breakdown product of sermorelin in urine. They carefully refined the sample clean-up steps and validated the method against anti-doping standards, checking things like sensitivity, reliability, and interference. The method could reliably detect the target peptides at very low levels (0.5 nanograms per millilitre or less). The authors concluded it is suitable and robust for anti-doping testing. The study does not examine whether these peptides work or are safe; it only provides a way to detect their use.
Community discussion
Community-reported · not verified
These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.
“People on Reta + Tesamorelin or CJC or Sermorelin - When do you pin GHRH?”
A user running retatrutide alongside a GHRH analog (tesamorelin, CJC-1295, or sermorelin) asks the community when they time their GHRH injections, seeking reported dosing-schedule practices for combined stacks.
“From Sermorelin to Tesamorelin+Ipamorelin”
A user describes switching from sermorelin to a tesamorelin plus ipamorelin stack. The thread compares the two growth-hormone secretagogue approaches and discusses why one might move between them.
“AOD9604 and Sermorelin? Sermorelin and ipamorelin?”
The poster asks whether AOD-9604 pairs sensibly with sermorelin, and whether sermorelin and ipamorelin are commonly stacked. Replies compare reported growth-hormone-axis combinations.
“Biohacking Advanced Level 4: Sermorelin”
Part of a serialized educational series in a Philippines biohacking community, this installment profiles sermorelin, a growth-hormone-releasing-hormone analog, presumably covering its mechanism and community usage context in explainer form.
“Tesamorelin vs. Sermorelin: Which Growth Hormone Secretagogue Makes More Sense? (2026 Research Guide)”
A comparative research guide weighing tesamorelin against sermorelin as growth-hormone secretagogues. It matters to readers evaluating differences between the two GHRH-based options.
Reported protocols (with caveats)
| USE | ROUTE | COMMON DOSE | FREQUENCY | TYPICAL CYCLE |
|---|---|---|---|---|
| Adult GH axis support (community-reported) | SC injection | 100–300 mcg | Once daily (before sleep); some report 5 days on / 2 days off | 3–6 months |
| Combination with ipamorelin (community-reported) | SC injection | 100–200 mcg sermorelin | 1–2× daily | 8–12 weeks |
Frequently asked questions
- Was sermorelin ever FDA-approved?
- Yes — the branded product Geref received two FDA approvals: a diagnostic formulation (NDA 19-863) approved in 1990 for testing pituitary GH reserve, and a therapeutic formulation (NDA 20-443) approved in 1997 for treatment of growth hormone deficiency in children. The manufacturer voluntarily withdrew Geref from the US market in 2008 for commercial, not safety, reasons; the FDA formally withdrew the marketing approval in June 2009. Compounded sermorelin preparations for adult off-label use are not an FDA-approved product and have not been evaluated in the clinical trials that supported Geref's approval.
- What are the known risks of sermorelin?
- The most commonly documented adverse events in paediatric trials were injection-site reactions (redness, swelling, pain) and, at lower frequency, flushing, headache, and nausea. A theoretical concern shared with all GH secretagogues is the potential for IGF-1-mediated effects over long administration periods, including a theorised relationship with cancer risk that has been identified epidemiologically (Pollak et al., 2004; PMID 15229476) but not established causally for exogenous GHRH stimulation. The safety profile in adults receiving compounded sermorelin for off-label purposes has not been established in controlled trials.
- How strong is the evidence for sermorelin in adults?
- Evidence for sermorelin in the community-discussed adult applications — body composition, anti-ageing, athletic performance — is insufficient. The controlled trial evidence is restricted to paediatric growth hormone deficiency, a different population and endpoint. Adult pharmacokinetic and clinical studies confirm GH stimulation, and a small open-label study in eleven healthy elderly men (Vittone et al., 1997; PMID 9005976) found increased nocturnal GH pulse amplitude but no significant change in IGF-1 levels. No adequately powered, double-blind, placebo-controlled trial in adult body composition or performance endpoints has been published.
- Is sermorelin the same as growth hormone?
- No. Sermorelin is a growth hormone-releasing hormone (GHRH) analogue — it stimulates the pituitary gland to produce and release the body's own growth hormone. It does not directly introduce exogenous GH. The clinical consequence of sermorelin administration depends on the pituitary's capacity to respond and on endogenous regulatory mechanisms, including somatostatin-mediated inhibition.
- Is sermorelin legal to buy or use?
- Compounded sermorelin is sold as a research chemical in the United States; it is not FDA-approved for adult use in its current compounded form. Regulatory status varies by country. In some jurisdictions it requires a prescription; in others it is unscheduled. Verify current status with a qualified legal or clinical professional.